ArticleBulletin of experimental biology and medicine2025
Potential Markers for Thyroid Neoplasms in the Upstream Analysis of the Plasma Proteome.
Article in Bulletin of experimental biology and medicine, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The reliability of existing diagnostic methods for thyroid neoplasms remains questionable, which necessitates the search for alternative approaches. The use of nontarget proteomic analysis for diagnosing oncological diseases is gaining traction and represents an efficient method for multiplex analysis. This study analyzed 372 blood plasma samples collected from patients with histologically confirmed thyroid pathologies treated at the National Medical Research Center for Endocrinology in 2019-2021. The samples were obtained prior to surgical intervention. Sample preparation involved the reduction and alkylation of disulfide bonds, followed by proteolysis and purification using specialized cartridges. Proteomic analysis was performed using nanoflow HPLC coupled with high-resolution mass spectrometry in a data-dependent acquisition mode. Peptides were identified using FragPipe software, and their suitability for biomarker discovery was assessed. From this analysis, 60 candidate proteins for thyroid disease biomarkers were identified, and sequences of 2930 peptides were evaluated. Further evaluation of nine candidate proteins revealed 31 peptides with high suitability scores for quantification. These peptides can be consolidated into a single biomarker panel that will be further developed for the risk stratification of patients with thyroid diseases.
Indexed as
Identifiers
40679521What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.